Switch theme
Sign up to access all valuation multiples
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
2015
627
LTM Revenue $228M
LTM EBITDA -$327M
-$105M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arcus Biosciences has a last 12-month revenue of $228M and a last 12-month EBITDA of -$327M.
In the most recent fiscal year, Arcus Biosciences achieved revenue of $258M and an EBITDA of -$269M.
Arcus Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arcus Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $117M | $258M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$291M | -$269M | XXX | XXX | XXX |
| EBITDA Margin | -249% | -104% | XXX | XXX | XXX |
| Net Profit | -$267M | -$307M | XXX | XXX | XXX |
| Net Margin | -228% | -119% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Arcus Biosciences's stock price is $8.
Arcus Biosciences has current market cap of $813M, and EV of -$105M.
See Arcus Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$105M | $813M | XXX | XXX | XXX | XXX | $-3.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Arcus Biosciences has market cap of $813M and EV of -$105M.
Arcus Biosciences's trades at -0.5x LTM EV/Revenue multiple, and 0.3x LTM EBITDA.
Analysts estimate Arcus Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Arcus Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$105M | XXX | XXX | XXX |
| EV/Revenue | -0.4x | XXX | XXX | XXX |
| EV/EBITDA | 0.4x | XXX | XXX | XXX |
| P/E | -2.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArcus Biosciences's NTM/LTM revenue growth is -29%
Arcus Biosciences's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.9M for the same period.
Over next 12 months, Arcus Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Arcus Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Arcus Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 121% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -104% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -133% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.9M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 47% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 174% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 220% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arcus Biosciences acquired XXX companies to date.
Last acquisition by Arcus Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Arcus Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Arcus Biosciences founded? | Arcus Biosciences was founded in 2015. |
| Where is Arcus Biosciences headquartered? | Arcus Biosciences is headquartered in United States of America. |
| How many employees does Arcus Biosciences have? | As of today, Arcus Biosciences has 627 employees. |
| Who is the CEO of Arcus Biosciences? | Arcus Biosciences's CEO is Dr. Terry Rosen, PhD. |
| Is Arcus Biosciences publicy listed? | Yes, Arcus Biosciences is a public company listed on NYS. |
| What is the stock symbol of Arcus Biosciences? | Arcus Biosciences trades under RCUS ticker. |
| When did Arcus Biosciences go public? | Arcus Biosciences went public in 2018. |
| Who are competitors of Arcus Biosciences? | Similar companies to Arcus Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arcus Biosciences? | Arcus Biosciences's current market cap is $813M |
| What is the current revenue of Arcus Biosciences? | Arcus Biosciences's last 12-month revenue is $228M. |
| What is the current EBITDA of Arcus Biosciences? | Arcus Biosciences's last 12-month EBITDA is -$327M. |
| What is the current EV/Revenue multiple of Arcus Biosciences? | Current revenue multiple of Arcus Biosciences is -0.5x. |
| What is the current EV/EBITDA multiple of Arcus Biosciences? | Current EBITDA multiple of Arcus Biosciences is 0.3x. |
| What is the current revenue growth of Arcus Biosciences? | Arcus Biosciences revenue growth between 2023 and 2024 was 121%. |
| Is Arcus Biosciences profitable? | Yes, Arcus Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
